Literature DB >> 9520936

Reed-Sternberg cell: survival in a hostile sea.

J Cossman1, C Messineo, A Bagg.   

Abstract

In contrast to the non-Hodgkin's lymphomas, little is known regarding the origin, genetics, and function of the Reed-Sternberg cell of Hodgkin's disease. Unlike other cancers, the neoplastic cell of Hodgkin's disease, the Reed-Sternberg cell, is vastly outnumbered by a surrounding intense inflammatory infiltrate. How this rare neoplastic cell originates, persists, and disseminates in a presumably hostile cellular environment has remained a mystery. Understanding the biology of the Reed-Sternberg cell has been impeded by the rarity of the cell in tumor tissue. Herein, we describe how the application of single-cell genetic analysis has revealed a clonal and, possibly, germinal center B-cell origin of the Reed-Sternberg cell. By phenotype and function, Reed-Sternberg cells are highly interactive with their cellular microenvironment through cell-cell adhesion, expression of members of the tumor necrosis factor receptor superfamily, and elaboration of cytokines. Perhaps by their mimicry of immune system cells with antigen-presenting function, Reed-Sternberg cells mediate the unusual clinical and pathologic features of Hodgkin's disease: intense tissue inflammatory infiltrate, fibrosis, and constitutional symptoms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520936

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

Review 1.  [Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].

Authors:  C Renné; M L Hansmann; A Bräuninger
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

2.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.

Authors:  F M Raaphorst; F J van Kemenade; T Blokzijl; E Fieret; K M Hamer; D P Satijn; A P Otte; C J Meijer
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

3.  Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status.

Authors:  J R Flavell; K R Baumforth; D M Williams; M Lukesova; J Madarova; V Noskova; J Prochazkova; D Lowe; Z Kolar; P G Murray; P N Nelson
Journal:  Mol Pathol       Date:  2000-06

4.  Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells.

Authors:  Donatella Aldinucci; Dalisa Poletto; Annunziata Gloghini; Paola Nanni; Massimo Degan; Tiziana Perin; Paola Ceolin; Francesca Maria Rossi; Valter Gattei; Antonino Carbone; Antonio Pinto
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 5.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

6.  Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.

Authors:  B Jungnickel; A Staratschek-Jox; A Bräuninger; T Spieker; J Wolf; V Diehl; M L Hansmann; K Rajewsky; R Küppers
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

7.  Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.

Authors:  U Kapp; W C Yeh; B Patterson; A J Elia; D Kägi; A Ho; A Hessel; M Tipsword; A Williams; C Mirtsos; A Itie; M Moyle; T W Mak
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

8.  Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease.

Authors:  M Glavina-Durdov; J Jakic-Razumovic; V Capkun; P Murray
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

9.  Association of TLR9-1237T>C; rs5743836 polymorphism with increased risk of Hodgkin's lymphoma: A case-control study.

Authors:  Sohaib Al-Khatib; Amin Shabaneh; Nour Abdo; Laith Al-Eitan; Abdel-Hameed Al-Mistarehi; Yousef Khader
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

10.  Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.

Authors:  D Re; C Wickenhauser; T Ahmadi; E Buchdunger; M Kochanek; V Diehl; J Wolf
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.